TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00740376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uniglide Mobile Bearing Unicondylar Knee System
Description: Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uniglide Fixed Bearing Unicondylar Knee System
Description: Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
Study: NCT01530243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine + Terazosin
Description: 2mg daily and 2mg BID
Study: NCT03430310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Diet
Description: The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
Study: NCT02006576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen three times daily for 48 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times daily
Study: NCT05818670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: long term follow up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: long term follow up
Study: NCT02747524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita Mamba peanut butter paste
Study: NCT02050412

Intervention type: OTHER
Group type: OTHER
Intervention: Cat fur scratch test
Study: NCT01097772

Intervention type: DEVICE
Group type: OTHER
Intervention: Implant of Ovation Abdominal Stent Graft System
Description: Single occurrence permanent implant of AAA device.
Study: NCT02384811

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes.
Study: NCT03547557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate 2000 strappable system
Study: NCT00278876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (Glivec)
Description: Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
Study: NCT02823639

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Study: NCT05095012

Intervention type: OTHER
Group type: OTHER
Intervention: Pediatric Acute Care Concussion Clinical Pathway
Description: MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
Study: NCT01453582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Flavonoids of Propolis dropping pill
Description: One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: total Flavonoids of Propolis dropping pill
Description: One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
Study: NCT04549207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bone modifying agent
Description: Use of bone modifying agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bone modifying agent
Description: Use of bone modifying agent
Study: NCT04155411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 70 mg of Dasatinib orally daily for 12 months
Study: NCT02682979

Intervention type: OTHER
Intervention: Medical files analysis
Description: Retrospective analysis of the medical files according to medical, social and geriatric criteria.
Study: NCT00567255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/bupropion SR 360 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Study: NCT02025153

Intervention type: OTHER
Group type: OTHER
Intervention: pain testing
Description: physical testing, psychological testing, genetics testing and functional brain imaging

Intervention type: OTHER
Group type: OTHER
Intervention: pain testing
Description: physical testing, psychological testing, genetics testing and functional brain imaging

Intervention type: OTHER
Group type: OTHER
Intervention: pain testing
Description: physical testing, psychological testing, genetics testing and functional brain imaging
Study: NCT05145270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Escitalopram+Sulforaphane
Description: Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Escitalopram+rTMS
Description: Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram(No-specified) 10-20mg/d, once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram(No-specified) 10-20mg/d, once per day.
Study: NCT01012934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Sodium Tablets, 70 mg
Description: 1 x 70 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax Tablets, 70 mg
Description: 1 x 70 mg, single-dose fasting
Study: NCT05081466

Intervention type: OTHER
Intervention: Dietary pattern
Description: (regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan)

Intervention type: OTHER
Intervention: Fruit and vegetable intake
Description: Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire

Intervention type: OTHER
Intervention: Meat intake
Description: Red meat, poultry, processed meat from food frequency questionnaire

Intervention type: OTHER
Intervention: Fish intake
Description: Intake of fish from food frequency questionnaire

Intervention type: OTHER
Intervention: Egg intake
Description: Intake of eggs from food frequency questionnaire

Intervention type: OTHER
Intervention: Dairy intake
Description: Intake of dairy products from food frequency questionnaire

Intervention type: OTHER
Intervention: Tea intake
Description: Intake of tea (drink) from food frequency questionnaire

Intervention type: OTHER
Intervention: Coffee intake
Description: Intake of coffee (caffeinated or decaffeinated) from food frequency questionnaire

Intervention type: OTHER
Intervention: Tea and coffee intake
Description: Combined intake of tea and coffee from food frequency questionnaire

Intervention type: OTHER
Intervention: Protein intake
Description: Estimated intake of protein, derived from food frequency questionnaire
Study: NCT04922866

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02953717

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Knife radiosurgery
Description: GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiation Therapy
Description: Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
Study: NCT01184690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-operator double-balloon endoscopy
Description: Single-operator double-balloon endoscopy
Study: NCT05081466

Intervention type: OTHER
Intervention: Calcium intake
Description: Estimated intake of calcium, derived from food frequency questionnaire

Intervention type: OTHER
Intervention: Vitamin D intake
Description: Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake
Study: NCT02576730

Intervention type: PROCEDURE
Intervention: ORIF
Description: surgery for foot and ankle fractures
Study: NCT01713465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer based Metabolic Syndrome educational program
Description: Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
Study: NCT03141398

Intervention type: DIAGNOSTIC_TEST
Intervention: Continuous Glucose Monitoring (CGM)
Description: Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.
Study: NCT01184690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dual-operator double-balloon endoscopy
Description: dual-operator double-balloon endoscopy
Study: NCT00925600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prefilled syringe for subcutaneous (SC) injection
Study: NCT02151825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: 3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of Maltodextrin per day
Study: NCT01536444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Momelan Technologies Epidermal Graft Harvesting System
Description: The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
Study: NCT03141398

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.

Intervention type: DIAGNOSTIC_TEST
Intervention: T2* MRI of the Pancreas
Description: MRI \[Magnetic resonance imaging\] of the pancreas which is safe and takes around 30 minutes.
Study: NCT04257474

Intervention type: BEHAVIORAL
Intervention: Self-Report Survey
Description: The self-report survey will be created using the Health Services Utilization Model (HSUM)

Intervention type: BEHAVIORAL
Intervention: Qualitative Interviews
Description: Researchers will randomly select 30 participants from group 1 and will use semi structured qualitive interviews exploring factors impacting utilization of screening breast MRI
Study: NCT01747317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR (PressureWire)
Description: Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
Study: NCT03520010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Externally-facilitated implementation
Description: NHs randomized to the externally-facilitated arm will attend the same kickoff meetings and have access to the same online resources as the control arm but will also be assigned a clinical coach and will have the opportunity to participate in a series of hosted peer-to-peer learning opportunities. The clinical coach will meet regularly with NH staff to guide the facility through implementation of the Wisconsin UTI Improvement Toolkit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internally-driven implementation
Description: Study NHs randomized to the control arm will participate in kickoff meetings introducing the different UTI toolkit components. The meeting will also cover topics on how to assemble a change team, how to use the different tools in the UTI toolkit, and how to track process and outcome measures to monitor progress. NHs assigned to the control arm will have access to a web-based data tracking tool that will allow them to trend a number of study outcomes (e.g., number of monthly urine cultures and UTI treatment events) in their facility over time. Instructions and educational tools will be made available as an online resource but otherwise NHs in the control arm will be expected to implement the Wisconsin UTI Improvement Toolkit using existing internal resources.
Study: NCT01446185

Intervention type: DEVICE
Group type: OTHER
Intervention: Oncotype DX breast cancer test
Description: The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
Study: NCT04366999

Intervention type: PROCEDURE
Intervention: SG
Description: SG involved a vertical gastric resection beginning 4-6 cm from the pylorus and ending 1-2 cm from the His angle, using linear staplers with the guidance of a 36 French intragastric bougie.

Intervention type: PROCEDURE
Intervention: RYGB
Description: RYGB entails the creation of a 15-30 mL (approximate) gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb.
Study: NCT00637741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everflex 200
Study: NCT01333150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranololhydrochlorid
Description: One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One single dose of placebo
Study: NCT00965874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate high dose
Description: 9 g infusion once during 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate low dose
Description: 4.5 g magnesium sulfate infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: serum salin
Study: NCT00226317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study: NCT01074541

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 0.375 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 0.375 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 0.75 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 0.75 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 1.5 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 1.5 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 1.5 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 3.0 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 3.0 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 3.0 SED x 4 in a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: 3.0 SED x 4 in a week
Study: NCT00089661

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 162 / Denosumab
Description: 60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
Study: NCT03261310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen or Placebo
Description: Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen or Placebo
Description: Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen or Placebo
Description: Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen or Placebo
Description: Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively.
Study: NCT02234661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareerAdvance®
Description: CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
Study: NCT00904345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50-60 Gy and 70 Gy
Description: Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
Study: NCT00972218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
Study: NCT04471610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day
Description: Serial measurements of NT-proBNP, sodium, potassium, and creatinine in the NT-proBNP-group vs. no serial measurements in control group. In the intervention group the body weight, vital parameters, therapy changes and adverse events are documented the above mention serial measurement every second business day.
Study: NCT03222063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play interventions
Description: The following play were included in play interventions i.e building blocks, paint, puzzles, crayons, doctor set, ludo, snake and ladder. All hospitalized children in experimental group received play interventions at bed side. Taking into consideration the busy clinical setting, each participant received continuously 1 hour of hospital play interventions each day for continuous 5 days. Although the hospitalized children were free to choose according to their choice but still the younger children would be engaged in play such as doctor set, Drawing etc. to obtain more sensory experience and older children were offered play interventions such as puzzle, building blocks, ludo etc.with high cognitive demand.